• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » MassDevice Q&A: Chris LaFarge

MassDevice Q&A: Chris LaFarge

June 9, 2009 By Brad Perriello

Chris LaFarge, president and CEO of MedicaMetrix, is betting on his firm’s ProstaGlove device to change the way doctors track and treat the prostate. The product is essentially a disposable rubber glove armed with sensors LaFarge says will provide a quantitative method for tracking the volume and growth rate of the prostate — the only human organ that never stops growing.

LaFarge talked with MassDevice about the Wayland-based company’s drive to create a new “gold standard” for digital rectal exams, the challenge of landing U.S. venture backing and why Europe may see the company’s first rollout.

MassDevice: How did you come to be involved with medical devices?

Chris LaFarge: I was originally trained as a biologist at Harvard. I did bio-medical research at Harvard, Beth-Israel Deaconess Medical Center and eventually went back and got a Yale MBA. I came out of that and a professor I’d studied strategic planning with decided to set up a first company in the natural resources area. I went on to start a number of others in that space [but] it was a ghastly business.

I started looking around for other areas where there was a need and I was talking with another guy who was a urologist. I was investigating an opportunity in anesthesia and we got talking and he said, essentially, “We have this problem: We stick our fingers up people’s butts, but we have no idea what the information means.”

So we started looking at it from a business point of view and we thought it was a good opportunity.

MassDevice: You’ve had some success on the investment trail in Europe, but not so much stateside. Why do you think that is?

CF: A lot of the [venture capital firms] around here are in pretty deep trouble. A number have announced trying to raise funds and failing, others are not opening new funds to focus on managing their existing funds. Some will fold after their current investments cash out. This has been going on for a year and a half. The recession we’re all worried about now started a year and a half ago in the VC world.

It’s all about the bank, which is why in Europe there seems to be funds. But they’re restricted by their fund rules to only do 50 percent of investment outside their country. We’ve raised $2 million and we’re trying to raise $4 million. We’re talking to three other European funds right now. If I had to predict, we’ll complete the raise in the next six months and it will be all European money.

MassDevice: What’s been the biggest lesson you’ve learned during this recession? What’s the takeaway?

CF: Never, ever, ever try to fund a company from VC sources.

I have funded everything that we’ve done [with past startups] with strategic money. But in this climate there weren’t the players with the capacity to do the raise whom we could identify, so we said, “Why don’t we do a traditional venture raise?”

Even before the recession started, VCs were all pretending to be merchant bankers looking for B rounds and C rounds — or even IPOs — not looking for startups, or looking for what they called “startups,” which were actually going concerns.

MassDevice: What’s the competition for the Prostaglove? How big do you think the market for it is?

CF: It’s a start-up, second-generation prototype we’re in the process of taking to the next stage. It’s lab bench-tested only. The prostate is the only organ in the body that continues to grow throughout your life. The question right now is, without knowing what the size and growth rate is, it’s very difficult to predict when these complications are going to happen. When it breaks they fix it, with surgery or partial resection. The idea behind this product is that if one could measure the size and volume of the prostate and get some sense of that growth rate, it essentially becomes a preventative maintenance approach similar to hypertension or cholesterol treatments.

Digital rectal exams are not a bad way to try to get a sense of the prostate, but they’ve now done some studies that show no correlation between the estimate from an exam and the actual size of the prostate. Standard practice is to do an exam every time you see a male patient over age 40, whether it’s once a year, once a quarter or once a month. The prostate grows, but it grows slowly. If you’re starting to do that measurement around age 40, problems might not arise until you’re in your 50s or 60s.

The market is urologists treating men over 45 with urinary problems. About 20 million exams are performed each year in the U.S. and in Europe it’s more like 40 million. I just read a projection that over the next couple of decades the number of men over 60 is going to triple. It’s a growing market in every sense of the word.

We’re preparing to try and go in that direction [to Europe]. CE Marking and 510k approvals are essentially the same thing — they’re made off the same data. Whether we launch first in the EU or the U.S. depends to a large extent on where the money comes from. If youre launching in Europe but you have a strong American base that’s a considerable advantage. In the EU the big thing they’re trying to figure out is the U.S. market, because it’s a big market. The EU is 27 countries, plus divisions within in each country. It’s a very complex market — it’s twice the size of ours in the U.S., but it’s very fragmented.

Filed Under: Business/Financial News, Urology Tagged With: MassDevice Q&A

In case you missed it

  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D
  • Abbott reports positive data on heart valve therapies
  • OncoRes Medical raises another $12.5M
  • NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia
  • Inogen appoints Agnes Lee as senior VP of investor relations, strategic planning
  • Google Health hires FDA’s chief digital health officer
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says

RSS From Medical Design & Outsourcing

  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS